| __timestamp | MannKind Corporation | Travere Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 79383000 | 59644696 |
| Thursday, January 1, 2015 | 108402000 | 79541000 |
| Friday, January 1, 2016 | 46928000 | 98015000 |
| Sunday, January 1, 2017 | 74959000 | 103958000 |
| Monday, January 1, 2018 | 79716000 | 103654000 |
| Tuesday, January 1, 2019 | 74669000 | 128951000 |
| Wednesday, January 1, 2020 | 59040000 | 135799000 |
| Friday, January 1, 2021 | 77417000 | 149883000 |
| Saturday, January 1, 2022 | 91473000 | 220206000 |
| Sunday, January 1, 2023 | 94314000 | 265542000 |
Unlocking the unknown
In the competitive landscape of the pharmaceutical industry, understanding the financial strategies of key players is crucial. MannKind Corporation and Travere Therapeutics, Inc. have shown distinct trends in their Selling, General, and Administrative (SG&A) expenses over the past decade. From 2014 to 2023, MannKind's SG&A expenses fluctuated, peaking in 2015 and 2023, with a notable dip in 2016. In contrast, Travere's expenses have consistently risen, with a significant increase of over 340% from 2014 to 2023. This upward trend suggests a strategic investment in administrative capabilities and market expansion. By 2023, Travere's SG&A expenses were nearly three times higher than MannKind's, highlighting differing operational strategies. These insights provide a window into how each company allocates resources to maintain competitiveness and drive growth.
Breaking Down SG&A Expenses: Sanofi vs MannKind Corporation
Biogen Inc. and MannKind Corporation: SG&A Spending Patterns Compared
Selling, General, and Administrative Costs: BeiGene, Ltd. vs MannKind Corporation
Genmab A/S vs Travere Therapeutics, Inc.: SG&A Expense Trends
Operational Costs Compared: SG&A Analysis of Intra-Cellular Therapies, Inc. and MannKind Corporation
Summit Therapeutics Inc. or MannKind Corporation: Who Manages SG&A Costs Better?
Who Optimizes SG&A Costs Better? Alpine Immune Sciences, Inc. or Travere Therapeutics, Inc.
Amneal Pharmaceuticals, Inc. vs Travere Therapeutics, Inc.: SG&A Expense Trends
Selling, General, and Administrative Costs: Amicus Therapeutics, Inc. vs Travere Therapeutics, Inc.
Comparing SG&A Expenses: ImmunityBio, Inc. vs MannKind Corporation Trends and Insights
Selling, General, and Administrative Costs: Ligand Pharmaceuticals Incorporated vs Travere Therapeutics, Inc.
Comparing SG&A Expenses: Amphastar Pharmaceuticals, Inc. vs MannKind Corporation Trends and Insights